About RNA exonuclease 4
RNA exonuclease 4 (REXO4) is a protein
from Homo sapiens identified by UniProt accession
Q9GZR2, 422 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | RNA exonuclease 4 |
|---|
| UniProt accession | Q9GZR2 |
|---|
| Gene | REXO4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 422 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (31)
Diseases linked to this target (Open Targets).
- alkaline phosphatase measurement · score 0.15
- Red cell distribution width · score 0.12
- erythrocyte count · score 0.12
- a disintegrin and metalloproteinase with thrombospondin motifs 13 measurement · score 0.11
- protein measurement · score 0.11
- blood group O · score 0.10
- blood protein measurement · score 0.09
- blood group B · score 0.09
- blood group AB · score 0.09
- blood group A · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9GZR2-F1 | alphafold | PREDICTED | 70.77 | — |
Amino-acid sequence (422 residues)
MGKAKVPASK RAPSSPVAKP GPVKTLTRKK NKKKKRFWKS KAREVSKKPA SGPGAVVRPP KAPEDFSQNW KALQEWLLKQ KSQAPEKPLV ISQMGSKKKP KIIQQNKKET SPQVKGEEMP AGKDQEASRG SVPSGSKMDR RAPVPRTKAS GTEHNKKGTK ERTNGDIVPE RGDIEHKKRK AKEAAPAPPT EEDIWFDDVD PADIEAAIGP EAAKIARKQL GQSEGSVSLS LVKEQAFGGL TRALALDCEM VGVGPKGEES MAARVSIVNQ YGKCVYDKYV KPTEPVTDYR TAVSGIRPEN LKQGEELEVV QKEVAEMLKG RILVGHALHN DLKVLFLDHP KKKIRDTQKY KPFKSQVKSG RPSLRLLSEK ILGLQVQQAE HCSIQDAQAA MRLYVMVKKE WESMARDRRP LLTAPDHCSD DA
Explore RNA exonuclease 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets